RxDoctor Payments Data

Alicia Day

Family · Concord, NHNPI 1821622119

Payments from drug & device makers

$811in general payments, 2019–2025

Across 12 payments — averaging $67.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$259
  • Abbott$183
  • Johnson & Johnson$99
  • Shockwave Medical, Inc$65
  • Boehringer Ingelheim$50
  • Novo Nordisk$50
  • plus $104 from 3 others

What the payments were for

  • Food & beverage$811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$811 in reported general payments places this provider in the 80th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$47,191
Medicare patients
397
Services billed
607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$132,072
XareltoRivaroxaban45$47,936
BrilintaTicagrelor43$37,891
EntrestoSacubitril/Valsartan39$34,693
Repatha SureclickEvolocumab16$13,355
JardianceEmpagliflozin13$9,593
Atorvastatin Calcium389$4,358
Metoprolol Succinate319$3,870
Dofetilide18$3,686
ClopidogrelClopidogrel Bisulfate235$2,636
Amiodarone Hcl41$1,926
Ezetimibe83$1,729
Rosuvastatin Calcium108$1,543
Torsemide44$1,514
Pantoprazole Sodium89$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$99$47,93645 claims
Boehringer IngelheimJardiance$50$9,59313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 713 family providers in New Hampshire.

Other family in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →